Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 27;14(1):85.
doi: 10.1038/s41408-024-01072-0.

Lower relapse incidence with HAPLO versus MSD or MUD HCTs for AML patients with KMT2A rearrangement: a study from the Global Committee and the ALWP of the EBMT

Yishan Ye  1 , Myriam Labopin  2 , Jia Chen  3 , Depei Wu  3 , Tobias Gedde-Dahl Sr  4 , Didier Blaise  5 , Gérard Socie  6 , Edouard Forcade  7 , Urpu Salmenniemi  8 , Sébastien Maury  9 , Jurjen Versluis  10 , Ali Bazarbachi  11 , Arnon Nagler  12 , Eolia Brissot  2   13 , Lin Li  1 , Yi Luo  1 , Jimin Shi  1 , Fabio Ciceri  14 , He Huang  15 , Mohamad Mohty  16   17 , Norbert Claude Gorin  18   19
Affiliations

Lower relapse incidence with HAPLO versus MSD or MUD HCTs for AML patients with KMT2A rearrangement: a study from the Global Committee and the ALWP of the EBMT

Yishan Ye et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Transplant outcomes of the HAPLO, MSD and MUD cohorts for adverse-risk KMT2Ar AML.
NRM, RI, LFS, OS, GRFS, and grade II–IV acute GVHD of the HAPLO, MSD, and MUD cohorts.
See this image and copyright information in PMC

References

    1. Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77. doi: 10.1182/blood.2022016867. - DOI - PubMed
    1. Pigneux A, Labopin M, Maertens J, Cordonnier C, Volin L, Socie G, et al. Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML) Leukemia. 2015;29:2375–81. doi: 10.1038/leu.2015.143. - DOI - PubMed
    1. van Weelderen RE, Klein K, Harrison CJ, Jiang Y, Abrahamsson J, Arad-Cohen N, et al. Measurable residual disease and fusion partner independently predict survival and relapse risk in childhood KMT2A-rearranged acute myeloid leukemia: a study by the International Berlin-Frankfurt-Munster Study Group. J Clin Oncol. 2023;41:2963–74. doi: 10.1200/JCO.22.02120. - DOI - PMC - PubMed
    1. Balgobind BV, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A, et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood. 2009;114:2489–96. doi: 10.1182/blood-2009-04-215152. - DOI - PMC - PubMed
    1. Sanz J, Galimard JE, Labopin M, Afanasyev B, Angelucci E, Ciceri F, et al. Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. J Hematol Oncol. 2020;13:46. doi: 10.1186/s13045-020-00882-6. - DOI - PMC - PubMed

Publication types

Substances